UBS AM
RPRX icon

UBS AM’s Royalty Pharma RPRX Stock Holding History

UBS AM’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Sell
3,453
-3,092,313
-100% -$161M ﹤0.01% 2730
2026
Q1 		$149M Sell
3,095,766
-23,099
-0.7% -$1.01M 0.03% 437
2025
Q4 		$121M Sell
3,118,865
-11,071
-0.4% -$422K 0.03% 453
2025
Q3 		$110M Sell
3,129,936
-947,063
-23% -$34.3M 0.02% 457
2025
Q2 		$147M Buy
4,076,999
+1,229,065
+43% +$40.7M 0.03% 456
2025
Q1 		$88.7M Buy
2,847,934
+226,048
+9% +$7.16M 0.02% 569
2024
Q4 		$66.9M Sell
2,621,886
-350,315
-12% -$9.29M 0.02% 604
2024
Q3 		$84.1M Buy
2,972,201
+174,874
+6% +$4.84M 0.02% 562
2024
Q2 		$73.8M Buy
2,797,327
+933,604
+50% +$25.9M 0.02% 527
2024
Q1 		$56.6M Buy
1,863,723
+379,518
+26% +$11.2M 0.02% 570
2023
Q4 		$41.7M Buy
1,484,205
+137,644
+10% +$3.78M 0.02% 635
2023
Q3 		$36.5M Buy
1,346,561
+189,561
+16% +$5.63M 0.02% 640
2023
Q2 		$41.7M Hold
1,157,000
– – 0.02% 598
2023
Q1 		$41.7M Buy
1,157,000
+66,299
+6% +$2.46M 0.02% 598
2022
Q4 		$43.1M Buy
1,090,701
+61,294
+6% +$2.56M 0.02% 588
2022
Q3 		$41.4M Buy
1,029,407
+92,791
+10% +$3.96M 0.02% 602
2022
Q2 		$39.4M Sell
936,616
-1,765
-0.2% -$72.4K 0.02% 597
2022
Q1 		$36.6M Buy
938,381
+22,699
+2% +$891K 0.02% 691
2021
Q4 		$36.5M Buy
915,682
+325,543
+55% +$12.6M 0.01% 731
2021
Q3 		$21.3M Buy
590,139
+16,704
+3% +$649K 0.01% 845
2021
Q2 		$23.5M Buy
573,435
+55,481
+11% +$2.36M 0.01% 852
2021
Q1 		$22.6M Buy
+517,954
New +$24.6M 0.01% 826

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's RPRX Position: Q2 2026 in Review

UBS AM reduced its Royalty Pharma (RPRX) stake by 100% in Q2 2026, selling an estimated $161M and leaving 3,453 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #2730.

UBS AM first reported a position in RPRX in Q1 2021 and has held it in 22 quarters since. The position peaked at $149M in Q1 2026. 648 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • UBS AM held 3,453 shares of Royalty Pharma worth $194K as of Q2 2026.
  • UBS AM sold 3,092,313 Royalty Pharma shares in Q2 2026, an estimated $161M.
  • Royalty Pharma made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2730 holding.
  • UBS AM first reported a position in Royalty Pharma in Q1 2021 and has held it in 22 quarters since.
  • UBS AM's Royalty Pharma position peaked at $149M in Q1 2026.
  • 648 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.